Abstract
Thiazolidinediones (TZDs), which are agonists of the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ), are effective at improving insulin sensitivity in patients with type 2 diabetes. However, major concerns have been raised in recent years about several adverse effects of TZDs. Now, writing in Nature, Choi et al. describe the development of a novel small-molecule non-agonist PPARγ ligand exhibiting potent antidiabetic activity in mice, without some of the side effects associated with TZDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
